Apollo Endosurgery develops devices that advance therapeutic endoscopy, focusing on alternatives to invasive surgical procedures to improve patient lives.

Apollo Endosurgery

Cascades Inc. produces, converts, and markets packaging and tissue products in Canada and the United States. The company operates through three segments: Containerboard, Specialty Products, and Tissue Papers. It manufactures containerboards, as well as converts corrugated products. The company also offers uncoated recycled paperboards for use in packaging converters and industrial users of headers and wrappers for the paper industry, as well as partitions that are used as protective packaging; honeycomb paperboards for the beer, wine, and spirits industry; laminated paperboards for food packaging and furniture backing industries; and specialty containers, structural components, and paperboard and fiber composites. In addition, it provides egg filler flats and egg cartons for egg processors and four-cup carriers for the quick-service restaurant industry; polystyrene foam trays for processors and retailers in the food industry; rigid plastic packaging products for food industry, processors, and retailers; and flexible films for frozen foods, bakery, and ice industries. Further, the company offers bathroom and facial tissues, paper towels, paper hand towels and napkins, and other related products and services under the Cascades PRO Signature, Cascades PRO Perform, Cascades PRO Select, Cascades PRO Tandem, and Cascades PRO Tuff-Job brands; and under the Cascades Fluff, Cascades Tuff, and Satin Soft labels, as well as private labels and other secondary marks. Additionally, it offers services to recover and process discarded materials for the municipal, industrial, commercial, and institutional sectors. The company sells its products through own sales force and external representatives. Cascades Inc. was incorporated in 1964 and is headquartered in Kingsey Falls, Canada.

Cascades Inc.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Brent Ratz

Arshad Quadri

Zoran Maricevic

Edwards Lifesciences Corporation

Encision develops and manufactures AEM® Shield™ Laparoscopic Surgical Instruments for improved patient safety in minimally invasive surgery, as per their self-described guidelines.

Metric
Company Name	Apollo Endosurgery	Cascades Inc.	Edwards Lifesciences Corporation	Encision
Symbol		CAS	EW
MSH ID	COM:APOLLOENDO	COM:CASCADES	COM:EDWARDS	COM:ENCISION
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Consumer Cyclical	Healthcare	Healthcare & Health Services
Industry	Medical Devices	Packaging & Containers	Medical - Devices	Medical Devices
Country	US	CA	US	US
Stage	Post-IPO Debt
Employee Count		9.80K	19.80K
Website	apolloendo.com	cascades.com	edwards.com	encision.com
LinkedIn			edwards-lifesciences
Founders

Metric
Market Cap		638.89M	56.51B	4.45M
Enterprise Value
Monthly Web Traffic	4.86K		232.86K
Web Traffic Growth	0.32		0.15
Valuation
Raised Capital	35M

Metric
Revenue	3.28B	6.00B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.34B	4.63B
EBITDA	399.67M	1.53B
Operating Income	28.30M	1.53B
Net Income	-53.76M	1.40B
EPS	-0.54	2.31
Diluted EPS	-0.54	2.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.41	0.77
Operating Profit Margin	0.04	0.27
EBITDA Margin	0.12	0.26
Net Profit Margin	-0.00	0.25
Return on Equity	-0.01	0.22
Return on Assets	-0.00	0.15
Return on Capital Employed	0.05	0.19

COM:APOLLOENDO

Apollo Endosurgery

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-46.55	36.59
P/B Ratio	0.79	7.86
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.23	9.40
EV Multiple	-1.52	30.96

Metric
Days Sales Outstanding	44.26	50.31
Days Payables Outstanding	120.26	54.32
Days Inventory Outstanding	83.69	309.03
Operating Cycle	121.67	359.90
Cash Conversion Cycle	44.98	306.62
Asset Turnover	0.97	0.64

Metric
Operating Cash Flow	360.76M	895.80M
Free Cash Flow	112.47M	629.50M
Cash Flow to Debt	0.26	1.40
Operating Cash Flow/Sales	0.11	0.15
Free Cash Flow Yield	-0.00	0.02

Metric
Cash & Equivalents	38.20M	1.14B
Accounts Receivable	67.20M	-141.20M
Inventory	401.79M	1.17B
Goodwill	340.25M	1.25B
Debt to Capitalization	0.53	0.09
Debt to Assets	0.43	0.07
Current Ratio	1.59	3.28
Quick Ratio	0.63	2.87

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-0.02	0.02
R&D to Revenue		0.18
SG&A to Revenue	0.17